BillionToOne (BLLN) Reaffirms 2025 Revenue Outlook of $293M to $299M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: NASDAQ.COM
- 2025 Revenue Outlook: BillionToOne expects fiscal 2025 revenue to range between $293 million and $299 million, indicating stable growth potential in the molecular diagnostics sector, with positive net operating income anticipated.
- 2024 Performance Review: For fiscal 2024, BillionToOne reported revenue of $153 million, reflecting significant growth compared to the previous year and demonstrating the company's increasing competitiveness in the market.
- 2026 Forecast: The company anticipates revenue for fiscal 2026 to be between $415 million and $430 million, with continued positive net operating earnings expected, highlighting strong business expansion and market demand.
- Analyst Expectations: An average of eight analysts forecasts BillionToOne to generate $296.24 million in revenue for 2025 and $393.61 million for 2026, indicating market confidence in the company's future growth trajectory.
Analyst Views on BLLN
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





